La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Tianjin Chase Sun PharmaceuticalLtd Salute del bilancio
Salute finanziaria criteri di controllo 5/6
Tianjin Chase Sun PharmaceuticalLtd has a total shareholder equity of CN¥8.9B and total debt of CN¥1.5B, which brings its debt-to-equity ratio to 16.5%. Its total assets and total liabilities are CN¥12.0B and CN¥3.1B respectively. Tianjin Chase Sun PharmaceuticalLtd's EBIT is CN¥385.5M making its interest coverage ratio 10. It has cash and short-term investments of CN¥1.6B.
Informazioni chiave
16.5%
Rapporto debito/patrimonio netto
CN¥1.48b
Debito
| Indice di copertura degli interessi | 10x |
| Contanti | CN¥1.62b |
| Patrimonio netto | CN¥8.92b |
| Totale passività | CN¥3.08b |
| Totale attività | CN¥12.01b |
Aggiornamenti recenti sulla salute finanziaria
Recent updates
These 4 Measures Indicate That Tianjin Chase Sun PharmaceuticalLtd (SZSE:300026) Is Using Debt Reasonably Well
Aug 02
There's No Escaping Tianjin Chase Sun Pharmaceutical Co.,Ltd's (SZSE:300026) Muted Earnings
Jun 12Tianjin Chase Sun PharmaceuticalLtd (SZSE:300026) Has Announced A Dividend Of CN¥0.03
May 22This Broker Just Slashed Their Tianjin Chase Sun Pharmaceutical Co.,Ltd (SZSE:300026) Earnings Forecasts
May 21Tianjin Chase Sun PharmaceuticalLtd's (SZSE:300026) Sluggish Earnings Might Be Just The Beginning Of Its Problems
Apr 04Analisi della posizione finanziaria
Passività a breve termine: 300026's short term assets (CN¥6.9B) exceed its short term liabilities (CN¥1.7B).
Passività a lungo termine: 300026's short term assets (CN¥6.9B) exceed its long term liabilities (CN¥1.4B).
Storia e analisi del rapporto debito/patrimonio netto
Livello di debito: 300026 has more cash than its total debt.
Riduzione del debito: 300026's debt to equity ratio has increased from 2.5% to 16.5% over the past 5 years.
Copertura del debito: 300026's debt is well covered by operating cash flow (88.7%).
Copertura degli interessi: 300026's interest payments on its debt are well covered by EBIT (10x coverage).